Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Rare Disease Pionee | Zevra Therapeutics emerges as a key player in rare disease treatments, with MIPLYFFA's successful launch for Niemann-Pick Disease Type C driving substantial growth |
Financial Momentum | Strong revenue growth and a robust cash position of $217 million provide Zevra with a runway into 2029, supporting ongoing research and expansion efforts |
Pipeline Potential | Explore Zevra's diverse pipeline, including OLPRUVA and celiprolol, as the company aims to address unmet needs in rare disorders and expand its market presence |
Market Valuation | Analysts set price targets ranging from $15 to $25 per share, reflecting optimism about Zevra's growth prospects and potential Priority Review Voucher sale |
Metrics to compare | ZVRA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZVRAPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.8x | 6.5x | −0.5x | |
PEG Ratio | 0.16 | −0.09 | 0.00 | |
Price/Book | 15.2x | 3.2x | 2.6x | |
Price / LTM Sales | 15.4x | 2.4x | 3.3x | |
Upside (Analyst Target) | 108.9% | 180.6% | 42.8% | |
Fair Value Upside | Unlock | 7.2% | 6.5% | Unlock |